

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT application of)
Tohru NATSUME et al.)
Application No. 10/581,969) Confirmation No. 8384
Filed: June 7, 2006) Group Art Unit: 1656
For: NOVEL INTERACTION BETWEEN) Examiner: Maryam Monshipouri
PROTEINS, AND THERAPEUTIC AGENT)
FOR DISUSE MUSCULAR ATROPHY OR)
METHOD ASSOCIATED WITH DISUSE)
MUSCULAR ATROPHY TAKING)
ADVANTAGE OF NOVEL INTERACTION)

THIRD RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


Sir:

In further response to the Supplemental Restriction Requirement mailed May 8, 2009, applicant further elects not only the claims of Group 1(F), but also the invention of Group 2 (i.e. ZNF216 and ubiquitin chain). This further election is made without traverse.

This response is accompanied by a Third Preliminary Amendment which appropriately amends claim 19 to reflect the election of Group 2.

Respectfully submitted,

Dated: July 22, 2009



Thomas W. Cole
Registration No. 28,290

Customer No. 25570

Roberts Mlotkowski Safran & Cole, P.C.
P.O. Box 10064
McLean, VA 22102
Telephone: (703) 677-3001